ClarificationNov 4, 2026, 04:04 PM
Baird Medical Addresses Share Price Volatility, Cites Strong Fundamentals
AI Summary
Baird Medical Investment Holdings Ltd issued a statement addressing recent volatility in its market share price. The company stated it is monitoring the fluctuations and is unaware of any material undisclosed reasons for the decline. Management believes the current market valuation does not accurately reflect the company's business fundamentals and growth potential. Baird Medical reiterated its commitment to its growth strategy and shareholder value. The statement also highlighted the company's progress with its FDA-cleared microwave ablation system for thyroid nodules, expansion of its technology portfolio, adoption by major U.S. institutions, and growing global commercial footprint.
Key Highlights
- Baird Medical is closely monitoring fluctuations in its ordinary share price.
- The Company is not aware of any material development or undisclosed reason for the recent decline in its share price.
- Baird Medical management believes the current market valuation does not reflect the strength of its business fundamentals and growth potential.
- The Company remains committed to executing its growth strategy and preserving shareholder value.
- Baird Medical's lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and launching in the U.S. for benign thyroid nodules.
- The company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.
- Baird Medical's MWA solutions have been adopted by leading U.S. institutions including Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital.
- The company is rapidly expanding its global commercial footprint, with sales reaching multiple continents.
Price Impact
More from BDMD